L’evento è accreditato per:
MEDICO CHIRURGO specialista in:
ematologia; gastroenterologia; malattie infettive; medicina generale (medici di famiglia)
INFERMIERE
BIOLOGO
N. PARTECIPANTI: 100
CREDITI FORMATIVI:
The landscape of hepatology has experienced a profound paradigm shift. While the success of direct-acting antivirals (DAAs) for HCV and potent nucleos(t)ide analogues for HBV has drastically reduced viral-related mortality, new challenges are emerging. The recent introduction of targeted therapies for Hepatitis Delta (HDV) marks a new milestone, yet the focus is rapidly pivoting toward the rising burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Alcohol-related Liver Disease (ALD). With the first pharmacological treatments for MASH finally entering clinical practice, the management of these conditions is becoming increasingly proactive. Simultaneously, the therapeutic arsenal for rare diseases like Primary Biliary Cholangitis (PBC) is expanding with next-generation molecules. Despite these advances, portal hypertension and hepatocellular carcinoma (HCC) remain critical threats. In this evolving scenario, the expansion of liver transplant criteria and the integration of multidisciplinary, personalized care—driven by technological innovation—are essential to further improving patient survival and quality of life.
Caricamento in corso…